- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02195024
Cardiac MRI After Pacemaker Replacement (MRI-rePACE)
Cardiac MRI After Replacement of Long Term Implanted PACEmakers by a MRI Conditional Pulse Generator (MRI-rePace)
Study Overview
Status
Intervention / Treatment
Detailed Description
The trial is designed
- To investigate the cardiac MRI related adverse event-free rate in patients with long term implanted coradial pacing leads (Fineline-II) after implantable pulse generator (IPG) exchange to a MRI conditional system (short term and long term): Safety.
- To assess the technical performance of MRI conditional pacemaker systems with long term implanted coradial pacing leads, for cardiac MRI (short term and long term): Effectiveness pacemaker.
To assess the image quality (IQ) and the diagnostic value (DV) of the cardiac MRI scans in patients with implanted MRI conditional systems: Effectiveness cardiac MRI.
2) To evaluate the clinical incidence of MRI procedures in the population of long term implanted pacemaker patients (long term-follow up)
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Nürnberg, Germany, D-90471
- Klinikum Nürnberg Süd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Approved clinical indication for pectoral pacemaker exchange (e.g. elective replacement indication (ERI), end of service (EOS))
Implantation of a CE certified / market released MRI conditional pacemaker (BSCI) consistent of
- a single or dual chamber MRI conditional pacemaker (BSCI) or
- Any comparable successor IPG (MRI conditional system, BSCI) compatible with
- Implanted Fineline-II-leads (BSCI), MRI conditional
Leads electrically intact and with stable and normal function
- The ascertained lead impedance is between 200 and 1500 Ohm.
- All pacing capture thresholds (PCT) do not exceed 2.0 V @0.4 or 0.5 ms in pacemaker dependent patients
Adherence to the MRI conditions of use is given
- Male or female 18 years or older
- Understand the nature of the procedure
- Give written informed consent
- Able to complete all testing required by the clinical protocol
- Ability to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms
- Patient body height greater or equal to 140 cm
- Pectoral implanted device
- Subjects who are able and willing to undergo elective cardiac magnetic resonance (MR) scanning without sedation (MRI-group)
- Subjects who are geographically stable and available for follow-up at the study center for the length of the study
Exclusion Criteria:
• Non MRI conditional leads implanted
- Pacing threshold(s) (at 0.4 or 0.5 ms) and/or sensing amplitude(s) and/or impedance(s) are not measurable
- Meet one or more of the contraindications for MRI including Psychiatric disorders, anxiety, claustrophobia Cardiac disorders that represent a contraindication to MRI
- Cardiac surgery already scheduled in the next three months
- Have other medical implants that may interact with MRI, e.g. abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve
- Have other metallic artifacts/components in body that may interact with MRI
- Subjects for whom a single dose of 1.0 milligram (mg) dexamethasone acetate may be contraindicated
- Subjects who require a legally authorized representative to obtain consent
- Subjects who are immediate candidates for an ICD
- Subjects with medical conditions that preclude the testing required by the protocol or limit study participation
- Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study
- Being pregnant
- Have a life expectancy of less than three months
- Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: cardiac MRI group
• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
|
• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
|
NO_INTERVENTION: No MRI group
Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety: cardiac MRI and pacing system related Serious Adverse Device Effects
Time Frame: 3 months after cardiac MRI
|
Primary outcome measure 1 (safety):
|
3 months after cardiac MRI
|
Effectiveness cardiac MRI: cMRI image quality (IQ) and diagnostic value (DV)
Time Frame: cMRI images done ≥ six (6) weeks after device exchange
|
Primary outcome measure 2 (Effectiveness cardiac MRI):
|
cMRI images done ≥ six (6) weeks after device exchange
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cMRI and pacing system related Adverse Device Effect
Time Frame: 1 and 3 months after cardiac MRI
|
The proportion of patients with a cMRI and pacing system related Adverse Device Effect (ADE)
|
1 and 3 months after cardiac MRI
|
Pacemaker performance under/after MRI (short and midterm) - Pacing capture threshold (PCT) rise (atrial and ventricular)
Time Frame: 1 and 3 Months after cardiac MRI
|
|
1 and 3 Months after cardiac MRI
|
Pacemaker performance under/after MRI (short and midterm): atrial or ventricular sensing amplitude
Time Frame: between Pre-MRI evaluation and at post-MRI interrogation at 1-month and at 3-month follow-up after cMRI
|
- P and R-wave sensing attenuation: o The proportion of patients with an atrial or ventricular amplitude decrease that exceed 50% between Pre-MRI evaluation and at post-MRI interrogation, at 1-month and at 3-month follow-up |
between Pre-MRI evaluation and at post-MRI interrogation at 1-month and at 3-month follow-up after cMRI
|
- Long term pacing capture threshold rise (atrial and ventricular)
Time Frame: Pre-MRI interrogation and at 2 years follow- up
|
|
Pre-MRI interrogation and at 2 years follow- up
|
- Long term P and R-wave sensing attenuation
Time Frame: between Pre-MRI interrogation and 2 years follow-up
|
The proportion of patients with an atrial or ventricular amplitude decrease that exceed 50% between Pre-MRI interrogation and 2 years follow-up
|
between Pre-MRI interrogation and 2 years follow-up
|
MRI procedures during long term-follow up
Time Frame: during a minimum of 2 years follow-up
|
Clinical incidence of MRI procedures during long term-follow up, device performance after repetitive MRI procedures
|
during a minimum of 2 years follow-up
|
periprocedural cardiac troponin
Time Frame: pre- and within 3 to 24 hours post-MRI
|
Cardiac high sensitive Troponin pre- and post-MRI as marker of thermal injury
|
pre- and within 3 to 24 hours post-MRI
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cMRI periprocedural observations / complaints
Time Frame: during cardiac MRI between pre- and post-MRI pacemaker interrogation
|
Periprocedural observations / complaints during MRI - Time interval: during MRI scanning, between pre- and post-MRI pacemaker interrogation |
during cardiac MRI between pre- and post-MRI pacemaker interrogation
|
IPG dysfunction
Time Frame: after cMRI at any follow-up until the end of the trial (minimum 24 months)
|
- Any IPG dysfunction (reset, reprogramming, over/undersensing, over-/underpacing, exit-block, loss of capture…), Battery changes
|
after cMRI at any follow-up until the end of the trial (minimum 24 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dirk Bastian, MD, Paracelsus Medical University Nürnberg
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMUN-DB-001-MRIPM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bradycardia
-
Augusta UniversityCompletedFetal BradycardiaUnited States
-
University of Maryland, BaltimoreCompleted
-
University of Sao Paulo General HospitalCompletedFetal Bradycardia | Hypertonic Uterine | CatecholaminesBrazil
-
Chun Chieh WangEnrolling by invitation
-
University of ExeterRoyal Devon and Exeter NHS Foundation TrustCompletedSVT | Vagal BradycardiaUnited Kingdom
-
Medical University of GdanskCompletedBradycardia During Pulling of EyeballPoland
-
Abbott Medical DevicesCompletedStandard Bradycardia Pacing IndicationFrance, Germany, Italy, Japan
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
South Western Ambulance Service NHS Foundation...Royal Devon and Exeter NHS Foundation Trust; Academic Health Science CentresCompletedEmergencies | SVT | Vagal BradycardiaUnited Kingdom
-
Unyime ItukRecruitingFetal Heart Rate or Rhythm Abnormality Affecting Fetus | Fetal Bradycardia Complicating Labor and Delivery | Fetal Bradycardia During LaborUnited States
Clinical Trials on cardiac MRI group
-
University of FloridaOcala Royal DamesActive, not recruitingBreast CancerUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); Nationwide Children's Hospital and other collaboratorsCompletedPulmonary Hypertension | Congenital Heart Disease | Pediatric Congenital Heart DiseaseUnited States
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial College Healthcare...WithdrawnMyocardial Fibrosis | Heart Failure | End Stage Renal Failure on Dialysis | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe)United Kingdom
-
St. Jude Children's Research HospitalRecruitingSepsis | Acute Respiratory Distress Syndrome | Cardiovascular ShockUnited States
-
University Medical Center GoettingenNot yet recruitingTetralogy of Fallot | Congenital Heart DiseaseGermany
-
Cedars-Sinai Medical CenterRecruitingHealthyUnited States
-
Medical University of GrazEnrolling by invitationPulmonary Hypertension | Elevated Mean Pulmonary Arterial Pressure | Normal Mean Pulmonary Arterial PressureAustria
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); University of Pittsburgh; University...Active, not recruitingCardiovascular DiseaseUnited States
-
University Hospital Birmingham NHS Foundation TrustUnknownTetralogy of FallotUnited Kingdom
-
University Hospital Birmingham NHS Foundation TrustUnknownCardiomyopathiesUnited Kingdom